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ABSTRACT Big medical data poses great challenges to life scientists, clinicians, computer scientists, and
engineers. In this paper, a group of life scientists, clinicians, computer scientists and engineers sit together
to discuss several fundamental issues. First, what are the unique characteristics of big medical data different
from those of the other domains? Second, what are the prioritized tasks in clinician research and practices
utilizing big medical data? And do we have enough publicly available data sets for performing those tasks?
Third, do the state-of-the-practice and state-of-the-art algorithms perform good jobs? Fourth, are there any
benchmarks for measuring algorithms and systems for big medical data? Fifth, what are the performance
gaps of state-of-the-practice and state-of-the-art systems handling big medical data currently or in future?
Finally but not least, are we, life scientists, clinicians, computer scientists and engineers, ready for working
together? We believe answering the above issues will help define and shape the landscape of big medical
data.
INDEX TERMS Big medical data, quantified self, disease classification, disease diagnosis, drug discovery,
publicly available data, benchmarks, algorithms, systems, multi-disciplinary collaboration.
I. INTRODUCTION
Unlike physics or chemistry, which the natural laws govern-
ing molecules are successful in describing [1], medical sci-
ence is not founded on first principals from which a healthy
or unhealthy human being or animal can be derived. Thus in
nature, one of the important features of medical science is its
data-driven mode: massive medical data stems from a wide
range of experiments or clinical practices that spit out many
types of information [2], and they provide the basis for our
clinician research and practice.
Big medical data poses great challenges to life scientists,
clinicians, computer scientists, and engineers. Even only con-
sidering computing requirements without delving into med-
ical details, Stephens et al. [3] compared genomics data—
one portion of big medical data, with three other major data
sources: astronomy, YouTube, and Twitter, and concluded big
medical data is either on par with or the most demanding of
the domains in terms of data acquisition, storage, distribution,
and analysis [3]. Unfortunately, big medical data has many
other dimensions of complexity other than data volume. For
example, medical data is much more heterogeneous than
those in the other domains [2]. Taking Alzheimer’ s dis-
ease (AD)—the most common age-related neurodegenerative
disease—as an example, clinicians and researchers [4] need
collect several types of data: clinical, genetic, imaging, and
biospecimen data for AD diagnosis. The heterogeneity of
multi-source data not only raises cognition difficulty (for
both clinician and computer scientist practitioners) , but also
poses the challenges of managing and analyzing those data
(for computer scientists and engineers). The worst of all, the
knowledge and skills in both fields are very professional,
which seriously challenges multi-disciplinary collaboration.
The purpose of this survey is to bridge the gap among life
scientists, clinicians, computer scientists, and engineers. To
define and shape the landscape of big medical data, we—a
group of life scientists, clinicians, computer scientists, and
1
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FIGURE 1: Relationships of Prioritized Tasks with Different
Medical Data.
engineers—sit together. We know it is impossible to perform
an exhaustive survey on all fields because of our knowledge
and time budget limits. Instead, we take a pragmatic approach
and focus on the prioritized tasks in clinician researches and
practices: Quantified Self—a specific movement to collect
and analyze different aspects of a personal daily life; Disease
Classification; Disease Diagnosis; and Drug Discovery. Fig-
ure 1 summarize the relationships among different medical
data with those prioritized tasks.
Also, our pragmatic approach lies in drafting this survey,
and we keep the readers in our mind: for each prioritized
task, we will help the readers—both life scientists, clinicians,
computer scientists and engineers answer the following ques-
tions. What data sets are publicly available? What are the
state-of-the-practice and state-of-the-art algorithms and sys-
tems? Do they perform a good job? If not, how about the
performance gap? Are there any comprehensive benchmark
suite to evaluate the algorithms and systems?
As big medical data is a fast-evolving field, the another
purpose of this survey is acting as a framework of defin-
ing and shaping the landscape of big medical data. For
example, understanding the root causes of disease is an
important task in utilizing medical data. Currently, we do
not include them because of its complexity and immaturity.
Meanwhile, for one prioritized task—disease diagnosis, we
only include three representative diseases to demonstrate
how to utilize medical data: Alzheimer’s disease (AD)—an
age-related neurodegenerative disease, Acute lymphoblastic
leukemia (ALL)—the most common cancer in children, and
breast cancer—the most common diseases among women.
In one word, we will keep expanding and updating state-of-
the-art and state-of-the-practice of the full spectrum of big
medical data.
Table 1 performs a comprehensive comparison of our
survey with the previous ones. To the best of our knowl-
edge, existing big medical surveys [5]–[15] target specific
problems and thus fail to cover the whole spectrum of the
above issues. Significantly different from the previous ones,
our survey paper covers the four prioritized tasks in clinician
research and practice: quantified self, disease classification,
disease diagnosis, and drug discovery from perspectives of
data sets, algorithms, systems, and benchmarks.
After thoughtful discussion and comprehensive survey
within our multi-disciplinary group, we gain several consen-
suses and insights as follows:
1) Big medical data is heterogeneous, high-dimensional,
embodying a large mixture of signals and errors [16].
The widely used data mining or machine learning
techniques heavily depend upon identifying weak as-
sociations instead of strong causation. The noisy nature
of experimental data may amplify the side effect of
our current ability to identify weak associations at the
cost of tolerating larger error thresholds [16]. From this
perspective, it may indicate that we need develop new
computing models and approaches in handling noisy
big medical data.
2) The publicly available big medical data sets are limited
in terms of not only its scale, but also its single data
source. For example, massive previous work utilizes
deep learning algorithms to analyze imaging data to
automatically diagnose disease. Unfortunately, all clin-
ician practices and researches, like disease classifica-
tion, disease diagnosis, and drug discovery need utilize
comprehensive data sources. So, we need to build multi
data-source knowledge base to advance state-of-the-
art and state-of-the-practice for disease classification,
disease diagnosis, and drug discovery.
3) The previous work demonstrates the potential of in-
corporating machine learning techniques into clinician
practices. However, its high accuracy is achieved on the
static data. In reality, the clinician practitioners work
in an open environment and handle open problems,
so we need set up the realistic benchmarks that can
mimic the way that the clinician practitioners handle
the dynamic data for different clinician purposes. Or
else, the achieved accuracy on static data does not make
sense in the clinician practices.
4) The sources and types of medical data are usually
multifarious and integrated. These dimensions are not
processed and learned individually, and conversely,
they are combined to detect and diagnose diseases
cooperatively. Under this circumstance, the storage and
processing systems are required to integrate different
data sources and types. To the best of our knowledge,
there exists no such a system that can support multi-
source and heterogeneous data storage and processing
in the big medical domain or even the other domains.
5) We discuss several prerequisites for the purpose of an
effective and efficient multi-disciplinary cooperation.
In the following sections, the related terminologies and
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TABLE 1: Summary of medical data surveys
Reference Publication year Prioritized tasks Data sets Algorithms Systems Benchmarks
Our 2018 Quantified self X X X X
Disease classification X X X X
Disease diagnosis X X X X
Drug discovery X X X X
[5] 2018 Quantified self X X X -
Disease diagnosis - X X -
Drug discovery - X - -
[6] 2018 Disease diagnosis X X X -
Disease surgery X X X -
[7] 2018 Disease diagnosis X X X X
[8] 2018 Disease diagnosis X X X
[9] 2018 Quantified self X X X X
[10] 2017 Disease diagnosis X X X -
[11] 2016 Quantified self X X X -
Disease diagnosis X X X X
Drug discovery X X - -
[12] 2016 Quantified self - X X -
Disease diagnosis X X X -
[13] 2016 Disease diagnosis X X X X
[14] 2016 Big data index X X X X
[15] 2015 Quantified self - - X -
Drug discovery - - - -
unique characteristics of big medical data are described in
Section II and Section III, respectively. In Section IV,
we will discuss four prioritized jobs in clinician research
and practises, and the related publicly available data sets. In
Section V, the state-of-the-art or state-of-practise algorithms
are discussed. The benchmark for measuring algorithms or
systems will be shown in Section VI. The performance gap
of the state-of-the-art or state-of-practise systems handling
big medical data will be explained in Section VII. Also, we
discuss multidisciplinary collaboration in Section VIII, and
conclusions will be drawn in Section IX.
II. TERMINOLOGIES
For the readers with different background, this section ex-
plains several important terminologies in both medical sci-
ences and computer sciences.
Genetics. Genetics [17] is a term that refers to the study
of genes and their roles in inheritance. As genes (units of
heredity) carry the instructions for making proteins, directing
the activities of cells and functions of the body, genetics
involves scientific studies of genes and their effects [17].
Omics. Omics [18] aims at the collective characterization
and quantification of pools of biological molecules that trans-
late into the structure, function, and dynamics of an organism
or organisms 1.
High throughput technologies. The generic term refers to
the technologies that allow exact and simultaneous examina-
tions of thousands of genes, proteins and metabolites [19].
For example, sequencing technologies [20] include a number
of methods that are grouped broadly as template preparation,
1The English-language neologism omics [18] informally refers to a field
of study in biology ending in omics, such as genomics, proteomics or
metabolomics.
sequencing and imaging, and data analysis. The unique com-
bination of specific protocols distinguishes one technology
from another and determines the type of data produced
from each platform [20]. In general, the automated Sanger
method is considered as a first-generation technology [20].
Second-generation sequencing (SGS) refers to sequencing of
an ensemble of DNA molecules with wash-and-scan tech-
niques [21]. Third-generation sequencing (TGS) refers to
sequencing single DNA molecules without the need to halt
between read steps [21].
Systems biology. The basic purpose of systems biol-
ogy [22] is the system-level understanding of a cell or an
organism in the context of molecular networks. The four
purposes of systems biology are as follows [22]: (1) under-
stand the structure of all the components of a cell/organism
up to a molecular level. (2) predict the future state of the
cell/organism under a normal environment, (3) predict the
output responses for a given input stimulus, and (4) estimate
the changes in system behavior upon perturbation of the
components or the environment.
Comparative Medicine. Comparative medicine [23] is a
distinct discipline of experimental medicine that uses animal
models of human and animal disease in translational and
biomedical research. Basically, it relates and leverages bio-
logical similarities and differences among species to better
understand the mechanism of human and animal disease [24].
Precision Medicine. Precision medicine [25] uses clin-
icopathological indexes and molecular profiling to create
diagnostic, prognostic, and therapeutic strategies individually
tailored to a patient.
Personalized medicine. Personalized medicine [26] refers
to the prescription of specific therapeutics that is the best
suitable for an individual on the basis of pharmacogenetic
3
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and pharmacogenomic information.
Data integration. The term data integration [27] refers
to the situation where, for a given system, multiple data
sources are available and studied integratively for knowledge
discovery.
Benchmarks. A benchmark [28] is the act of running a set
of computer programs or other operations, so as to assess
the relative performance of an object, i.e., a system or an
algorithm.
III. WHAT ARE THE CHARACTERISTICS OF BIG
MEDICAL DATA?
There are four significant characteristics of big medical
data.
First, big medical data is either on par with or the most
demanding of the domains 2 in terms of data acquisition, stor-
age, distribution, and analysis [3]. There are several reasons
underlying the boom of big medical data. On one hand, a sig-
nificant fraction of the world’ s human population will have
their genomes sequenced because of the promise of precision
medicine or personalized medicine [3]. On the other hand,
for medicine, just having the genome will not be sufficient,
and other relevant omics data sets will be definitely collected,
i.e, transcriptome, epigenome, proteome, metabolome, and
microbiome sequencing, from different tissues to compare
healthy and diseased states [29] [30] [3].
Second, medical data is much more heterogeneous than
those in the other domains [2]. On one hand, they stem
from a wide range of experiments that spit out many types
of information [2]. In summary, extensively-used medical
data consist of four types: sequence data, 3D-structure data,
multivariate data, and network data [22]. The challenge for
integrating heterogeneous data lies in deriving meaningful
interpretable correlations and causation [16]. For example,
direct correlation analyses between transcriptomics and pro-
teomics profiles are not valid in eukaryotic organisms [16].
On the other hand, there are diversity of existing data types
and formats, each one compliant to a different standard,
which results in data heterogeneity [27] [31].
Third, medical data is high-dimensional [16]. It is widely
recognized that multiple dimensions must be considered si-
multaneously so as to understand biological systems from a
perspective of systems biology, and performing analytics on
high-dimensional data often results with poor interpretabil-
ity [32]. The reliability of models probably decreases with
each added dimension (i.e. increased model complexity) for
a fixed sample size (i.e. bias-variance dilemma) [33]. All
estimate instability, model overfitting, local convergence, and
large standard errors compromise the prediction advantage
provided by multiple measures [16].
Fourth, medical data is coupled with the noisy nature of
experimental data, and especially omics data embody a large
2Stephens et al. [3] compared genomics data—one portion of big medical
data, with three other major generators of Big Data: astronomy, YouTube,
and Twitter.
mixture of signals and errors [16]. The widely-used data
mining or machine learning techniques heavily depend upon
identifying weak associations instead of strong causation.
The noisy nature of experimental data, which is often found
in Comparative Medicine, may amplify the side effect of our
current ability to identify weak associations at the cost of
tolerating larger error thresholds [16]. In other word, the pop-
ular data analytics techniques may fail in handling mixture
of signals and errors. Biological systems include non-linear
interactions and joint effects of multiple factors that make
it difficult to distinguish signals from random errors [16],
which has two implications: first, it is important to minimize
sources of error with omics data [16]. Second, we need to
develop new computing models and approaches in handling
noisy big medical data.
IV. WHAT ARE THE PRIORITIZED TASKS IN CLINICIAN
RESEARCH AND PRACTICES?
In this section, we summarize the prioritized tasks in clin-
ician research and practices utilizing big medical data sets.
We mainly focus on four prioritized tasks: quantified self,
disease classification, disease diagnosis, and drug discovery.
For each task, we answer the same question: do we have
enough publicly available data sets?
A. QUANTIFIED SELF
So far, there is no uniform definition for quantified self (in
short, QS). Wolf et al. [34] first propose QS in 2007, which
uses technologies and equipments to record and analyze
the body [35]–[37]. In this paper, we adopt the definition
of QS in Wikipedia [38]—QS is a specific movement that
integrates technology into data acquisition in a personal daily
life [38]. We collect data in terms of biological, physical,
behavioural, or environmental information, like food con-
sumed, the quality of air, mood, and performance, whether
mental or physical [38], [39]. After analysing the data, QS
equipments or apps will provide suggestions or warnings for
users.
Zhu et. al [39] summarize four applications in QS, such
as Daily Health Management [40]–[42], Disease Preven-
tion [43]–[45], Chronic Disease Management [46]–[48], and
Out-of-hospital rehabilitation [49]–[51]. Personal data are
continuously tracked and recorded through smart wearable
devices [40]. In daily life, tracking records are analyzed to
provide suggestions and warning, which can also be shared
among friends and families [41], [42]. Data collected by
QS tools helps pinpoint the root cause of disease early
and achieve early treatment to prevent disease [43]. QS
apps transfer the data to the hospital’s medical record sys-
tem and monitoring center, and provide early warning and
corresponding diagnosis and treatment opinions in chronic
disease [48]. And with portable quantitative instruments,
patients can monitor self at home and use computer software
to ask doctors for advice remotely for regular review after
surgery [51].
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1) Publicly available data sets
With the improvement of economic and the development
of technology, QS data is becoming more and more im-
portant in the field of health management and personalized
medicine [26], [52]. However, most of QS data sets are
limited to human behaviour. Moreover, the size of data set is
small, and only collected from several people or a dozen peo-
ple. There is no comprehensively public access database for
user-contributed data of QS [52]. The communities should
establish a public repository where individuals could upload
any types of QS data [53]. Several public database of QS data
are as follows.
HAR (Human Activity Recognition) dataset is an impor-
tant data category of QS, which is of great significance
in improving walking stability, recognizing motor disor-
ders, evaluating surgical outcomes, and reducing joint load-
ing [54]. At present, several HAR datasets have been re-
leased. Daphnet freezing of gait dataset [55] is collected from
patients with the Parkinson’s disease. The dataset includes
10 users, including 1,140,835 samples [55]. The samples
are marked as "frozen" or "non-frozen" [55]. WISDM Ac-
titracker dataset [56] contains 1,098,213 samples belong to
28 users and 6 distinctive activities of sitting, jogging, walk-
ing, climbing, and standing stairs. They collected the data
samples from Android phones [56]. Actitracker [57] con-
tains several daily activities, including "jogging", "walking",
"ascending stairs", and "descending stairs",and etc., which
are collected using a cell phone in their pocket with 20 Hz
sampling rate. Hand Gesture dataset [58] contains data on
different types of human hand movements. Table 2 shows
seven public QS datasets.
The National Health and Nutrition Examination Survey
(NHANES) [59], which can access the health and nutri-
tional status, is a program designed for the United States
(www.cdc.gov/nchs/nhanes/). The NHANES data set is avail-
able on Internet through an extensive series of publications
and articles in scientific and technical journals [59]. Open
Humans [60] is a platform that allows you to upload, connect,
and privately store your personal data – such as genetic,
activity, or social media data (www.openhumans.org/).
B. DISEASE CLASSIFICATION
Disease classification is a task that groups entities together
according to their similarities, which is an important step in
precision medicine and of great significance to the quanti-
tative study of the medicine phenomenon [61], [62]. Nowa-
days, it has been widely used in academic medicine [63].
However, existing disease taxonomy is often focused on
physiological characterizations and clinical appearance of
diseases, with little reference to the diseases mechanism [64],
[65]. Constructing a more accurate classification of the dis-
eases that can reflect the diseases mechanism is essential
towards fully understanding the entities.
With the development of the biotechnology, computer
technology and medical technology, the molecular data is
growing rapidly. This data provides new knowledge of the
TABLE 2: Overview of QS datasets. HAR means Human
Activity Recognition.
Name Task Instance Types Year
Open
Humans [60]
Data Analysis - genetic,
activity, or
social media
data
2015-
present
Hand
Gesture [58]
HAR sampling rate is
32 samples per
second
time series data 2014-
present
WISDM [56] HAR 1, 098, 213
samples
time series data 2011-
present
Actitracker [57] HAR 29, 000 frames time series data 2011-
present
Daphnet [55] HAR 1, 140, 835
samples
time series data 2010-
present
NHANES [59] Food
Consumption
- text 1960-
present
diseases on a molecular level, and deepens our understanding
of the disease. Thus, we can reclassify the diseases according
to the new input—the molecular biology information (such
as the genomic data of the tumour).
1) Publicly available data sets
Encouraged by the concept of precision medicine, most of
the researches on reclassifying the diseases focus on the
molecular biology. Besides, according to [66], for the pur-
pose of building a new effective system of disease taxon-
omy, other comprehensive data concerning clinical medicine,
environment and the state of individual health, which is
expected to be accumulated, is also indispensable. As shown
in Table 3, there are many publicly available data sets which
are qualified for disease classification. So far the publicly
available data mainly includes the genomic information of
diseases like different kinds of cancers and clinical reports.
However, the datasets relating to the environment and the
state of individual health are rarely publicly accessible since
they involve the patient privacy. Several representative public
datasets containing genome, clinical medicine, circumstance
and the health status of patients are described as below.
The Cancer Genome Atlas data set
The Cancer Genome Atlas (TCGA) data set is the most
popular genetic dataset, which focuses on collecting the data
of the cancer patients. So far, TCGA has collected approx-
imately 7000 human tumors [70]. And, it contains many
types of data such as measurements of somatic mutations,
copy number variation, mRNA expression, et al [70]. One
of the most important purpose of TCGA is to obtain the
valuable insights of the heterogeneity of different cancer
subtypes [75]–[78].
European Genome-phenome Archive(EGA)
EGA provides over 4 thousand datasets, consisting of in-
dividually distinguishable data in phenotype and gene. Those
data are collected from the research of biomedicine, and
can merely be used for legally genuine research purpose
with permission by creating accounts [68]. Specifically, EGA
contains approximately 710 DNA samples without plasma
5
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TABLE 3: Data set for disease classification
Name Task Instances Types Year
APGI [67]
Expediting the transformation from research
detection to the improvement of the
treatment for pancreatic cancer patients.
More than 4,000 cases genomic and clinical data 2009 - present
EGA [68] Offering free data and services of biologicalinformation. Over 6.25 million cases
Data of phenotype and
gene 2007 - present
ICGC [69] Describing cancer genomes. 1.52 PB genomic and clinical data 2007 - present
TCGA [70] Enhancing the avoidance, diagnosis, andtherapy of cancer. 33096 cases genomic data 2000 - present
GEO [71]
Offering a robust, multi-functional database
and effective tools to the query and
analysis of the database.
2,680,676 samples genomic data 2000 - present
CCLE [72] A transformation from genomics of cancercell into cancer division.
Over 1100 cell lines contain-
ing genetic information.
genomic and cell lines
data 2000 - present
Sanger [73] Genomic detection and comprehensionon the Earth.
More than 1000 human
Genomes genomic data 1992 - present
Truven
Marketscan [74]
Providing health improvement resolutions set
up from complete data, progressive
analysis and related specialists.
Roughly 55 million claim
every year.
genetic, environmental
and other medical
insurance data
1970s - present
cell and 428 white blood cell samples collected from over
4 hundred patients with metastatic prostate cancer.
Australian Pancreatic Cancer Genome Initiative
(APGI) data set
APGI is a part of the International Cancer Genome
Consortium—a global research enterprise of over 100 sci-
entists, clinicians and allied health professionals involved
in pancreatic cancer research and care [67]. APGI contains
over 4,000 pancreatic cancer patients in the database, with
a range of prospectively collected and archived biospec-
imens [67]. Every biospecimen is coupled with detailed
clinico-pathological data, including past medical history,
treatment data and detailed disease outcomes [67].
Cancer Cell Line Encyclopedia (CCLE) data set
CCLE is a cooperation among Novartis Institutes for
Biomedical Research, Genomics Institute of the Novartis
Research Foundation, and the Broad Institute [72]. The
project has three purposes: portray the features of gene and
pharmacology of a large amount of cancer, promote synthetic
analysis of connecting special susceptibility of pharmacology
concerning the patterns of genome, and transform compre-
hensive genomics of cancer cell into division of human
cancer [72]. The web site [72] provides publicly available
genetic dataset that can be displayed in visualized methods.
The data set, involving more than 1 thousand related infor-
mation of cell lines, can be exploited to quantitative analysis
of cancer and research of cancer reclassification according to
gene and cell lines.
Truven Marketscan data sets
Truven Marketscan is a synthetic platform of the IBM
Watson HealthTM business providing health improvement
resolutions [74]. The clinical information of patients and the
accumulation of over 50 million medical insurance claims
every year are included, some of which, according to the de-
scription of the platform, are accessible for the aim of relative
research with a fee. The medical insurance information can
be applied to various aspects of medical research, especially
disease classification concerning precise medicine due to the
genetic and environmental information of plenty of patients.
C. DISEASE DIAGNOSIS
Disease diagnosis is the process of determining which
disease or condition explains a person’s symptoms and
signs [79]. Early diagnosis wins time and money for pa-
tients [80]. Nowadays, with the development of techniques,
the diagnosis method has improved greatly. First, the devel-
opment of genomics techniques makes genetic data play an
important role in diagnosis. For example, gene mutations are
used to classify acute myelocytic leukemia (AML) [81], [82],
and two gene mutations have been included in the classifica-
tion of myeloid neoplasms and AML by WHO [83]. Second,
electronic health records (EHRs) have increased dramatically
recently. For example, 75.5% of US hospitals had a basic
EHR system [84] by 2014. Based on EHRs, Rajkomar et
al. [85] propose a fast healthcare interoperability resources
(FHIR) format, making it possible to make the most of EHRs
including free-text notes. In the following, three common
diseases that Alzheimer’s disease (AD)—age-related neu-
rodegenerative disease [86], Acute lymphoblastic leukemia
(ALL)—the most common cancer in children [87] and breast
cancer—the most common diseases among women are dis-
cussed in detail.
1) Representative disease diagnosis
Alzheimer’s disease (AD) diagnosis
AD is the most common age-related neurodegenerative
disease resulting in an irreversible loss of memory and other
cognitive functions in elderly people worldwide [86]. In
6
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2006, the number of individuals with AD is 26.6 million [88].
By 2050, this number will quadruple, by which time, 1 in 85
persons worldwide will be living with AD [88]. According
to the order of severity, patients are classified as normal,
mild cognitive impairment (MCI) or AD [4]. Medical imag-
ing of brains are usually used to diagnose AD, which is
time consuming if the work is done manually. To tackle
the problem, many automatic diagnostic systems have been
developed. Among them, convolutional network (CNN) is
the most prevalent method and has good performance [10].
Acute lymphoblastic leukemia (ALL) diagnosis
ALL is the most common cancer in children [87] with a
peak incidence at 2-5 years old [80]. Without timely treat-
ment, children with this serious blood pathology will die in
a few weeks [80]. Early diagnosis helps provide timely and
proper treatment for patients [80]. Microscopic examination
of blood or bone marrow smears is the only effective way
to leukemia diagnosis [89]. Generally, the method can be
tackled by a classic sequence of steps: (1) enhancing image,
(2) identification of white cells, (3) feature extraction, (4)
classification [80]. Besides image analysis, genomics stud-
ies have been introduced to inform disease classification in
recent years [82].
Breast cancer diagnosis Breast cancer has become one of
the most common diseases among women that leads to death.
Breast cancer can be diagnosed by classifying tumors. There
are two different types of tumors, such as malignant and
benign tumors. Doctors need a reliable diagnostic procedure
to distinguish between these tumors [10]. Generally, it is very
difficult to distinguish tumors even by the experts. Therefore,
an automatic diagnostic system is needed to diagnose the
tumors. The detection of breast cancer consists of three
subtasks [90]: (1) detection and classification of mass-like le-
sions, (2) detection and classification of micro-calcifications,
(3) breast cancer risk scoring of images. By using and
extending the results from the fields of machine learning,
statistics, image processing and optimization, highly accurate
diagnosis of breast is expected to be done even by untrained
users.
2) Publicly available data sets
Alzheimer’s disease (AD) diagnosis
Different materials such as clinical, cognitive, imaging,
genetic, and biochemical biomarkers can all be used to
define the progression of AD, and several researches try to
determine the relationships between those data [4]. ADNI
and BioFINDER are two longitudinal studies for AD, which
provide comprehensive data set of AD and have been used
widely by researchers. However, several researches indicate
that the data is still inadequate for solving the real problem.
For example, the AD DREAM Challenge [91] aims to bench-
mark state-of-the-art algorithms in predicting AD based on
publicly genetic and imaging data. However, the result is not
so perfect, and one possible reason is that the data used to
train model is inadequate.
As a longitudinal multi-center study designed to develop
clinical, imaging, genetic, and biochemical biomarkers for
the early detection and tracking of AD, the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) [4] provides compre-
hensive data for AD. Since its foundation in 2003, it has made
major contributions to AD research. Now it contains 483
subjects diagnosed with elderly control, 1001 subjects with
MCI, and 437 subjects with AD. ADNI researchers collect
several types of data: clinical data, genetic data, imaging data,
and biospecimen data. Clinical dataset comprises recruit-
ment, demographics, physical examinations, and cognitive
assessment data saved as comma separated values (CSV)
files. Genetic data contains genotyping and sequencing data.
Images such as magnetic resonance imaging (MRI) and
positron emission tomography (PET) are available. Biospec-
imens includes blood, urine, and cerebrospinal fluid (CSF).
Swedish Biomarkers For Identifying Neurodegenerative
Disorders Early and Reliably (BioFINDER) [92] is another
longitudinal study, aiming to develop methods for early and
accurate diagnosis of AD and Parkinson’s disease (PD). It
comprises more than 1600 subjects which undergo examina-
tions of advanced MRI, CSF and plasma analysis, amyloid
and tau PET, clinical assessments and neuropsychological
examinations [92].
Acute lymphoblastic leukemia (ALL) diagnosis
There are many comprehensive dataset for caners (e.g.
TCGA). But as a branch of cancer, the data for ALL is
relatively decentralized. Blood or bone marrow smears are
key materials to diagnose ALL [89]. ALL-IDB is a public
image database for ALL that has been studied widely. How-
ever, several researchers [93], [94] claim that hundreds of
images are not enough to build a robust CNN, so more public
data is still needed for ALL diagnosis. Besides, genomic
information is also provided for ALL such as TARGET [87]
and BioGPS [95].
Acute lymphoblastic leukemia image database (ALL-
IDB) [80] is a public dataset of microscopic images of
blood samples, based on which researchers can evaluate their
segmentation and classification algorithms. The format of
the images is JPG with 24 bit color depth and resolution
2592 x 1944. ALL-IDB1 contains 108 images of 39000
blood elements, where lymphocytes are manually labeled by
experts. Cropped areas of interest of cells belonging to ALL-
IDB1 are collected as ALL-IDB2 dataset.
Therapeutically applicable research to generate effective
treatments (TARGET) [87], a project of national institutes of
health (NIH), determines molecular changes that drive child-
hood cancers by genomic approaches. The ALL pilot phase
(Phase I) has produced genomic profiles of nearly 200 B-
cell ALL patient cases for molecular alterations. Nucleic acid
samples data, extracted from peripheral blood and bone mar-
row tissues, is included in each fully-characterized case. The
dataset consists of clinical information, tissue pathology data,
chromosome-specific copy number alterations, sequence data
of single amplicons, and mutations. BioGPS [95] is a gene
annotation portal, which supplies serval ALL genetic dataset,
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TABLE 4: Data set for AD diagnosis
Name Task Instances Types Modality Year
ADNI Detect AD at early stage 483 EC subjects, 1001
MCI subjects, 437 AD
subjects
Clinical, genetic,
imaging, biospec-
imen
MRI, PET,
TXT
2003-
2018
BioFINDER Detect AD and PD at early
stage
more than 1600 subjects Clinical, genetic,
imaging, biospec-
imen
MRI, PET,
TXT
2013-
2018
Abbreviation: AD = Alzheimer disease; EC = elderly controls; MCI = mild cognitive impairment; PD = Parkinson’s disease.
the biggest of which contains 207 samples provided by
children’s oncology group (COG) study P9906 for high-
risk pediatric ALL [96]. For each subject the dataset pro-
vides genome structure information such as BCR-ABL, E2A-
PBX1, TEL-AML and clinical information such as central
nervous system (CNS) status, white blood cell (WBC), age,
gender and etc.
Breast Cancer Diagnosis
Digital imaging databases are needed for mammographic
image analysis research. For the sake of accurate labeling
of images, free-text report databases are necessary as well,
which can be leveraged to turn the reports into accurate
annotations automatically for network training [10]. Besides,
it is recommendable to use gene expression databases to be
able to connecting cancer phenotypes to genotypes.
So far, all three types of breast databases mentioned
above have been developed. Unfortunately, most of the large
databases are not publicly available and many stale databases
are still in use.
INbreast, mini-MIAS, DDSM, BCDR-FMR, Breast Can-
cer Wisconsin Dataset and TCGA-BRCA are the most
frequently-used mammographic mass classification datasets.
These databases do represent a constructive and practical
contribution to computer vision research in mammography
(in short, MG) and it is expected that they will encourage
the production of more extensive collections of data. Table
6 shows the most commonly-used datasets for diagnosing
breast cancer.
The INbreast database contains 115 examples, which in-
cludes 90 examples from breast-affected women and 25
examples from mammectomy women [97]. The INbreast
database includes many types of lesions [97]. The compara-
tive advantages of the INbreast database are its huge amount
of examples together with accurate labels [97]. It is glad to
see that this database can strongly support the future work on
breast cancer diagnosis [97].
The Mammographic Image Analysis Society (MIAS) is
a digital mammography (in short, MG) dataset. It includes
322 digital images, and contains both abnormal examples
and normal examples [98] . The entire database, when com-
pressed, occupies less than 2 GBytes fitting onto a single 8
mm magnetic tape. Copies are available for research pur-
poses. The mini-MIAS database is available for scientific
research at no cost, provided that they must abide by the
licence agreement when using the imagery.
The Digital Database for Screening Mammography
(DDSM) contains digitized mammograms together with re-
lated labels and other detailed information [99]. The DDSM
database is freely available through the website [99].
The Breast Cancer Digital Repository (BCDR-FMR) is a
comprehensive labeled dataset, which provides digital con-
tent (digitized film mammography images) and associated
metadata (clinical history, segmented lesions BI-RADS clas-
sified, image-based descriptors, biopsy proven, etc.). The
BCDR-FMR establishes a novel reference to develop breast
cancer diagnosis methods [100].
The Breast Cancer Wisconsin (Diagnostic) Dataset is com-
paratively abundant in examples, including 569 patients, and
for each instances, there are 32 attributes to describe it and
ten features to measure it. There are both qualitative and
quantitative features in the dataset. All feature values are
recorded with four significant digits. This dataset consists of
212 malignant cases and 357 benign cases [101].
Nowadays, tumor gene expression analytical techniques
based on DNA microarray have been applied to diagnose
breast cancer [102]. TCGA-BRCA project has explored the
most comprehensive gene expression database. However,
analytical algorithms, which can solve gene expression-based
diagnosis problems, have yet to be established [102].
Traditional PACS (Picture archiving and communication)
systems preserve structured reports described by radiolo-
gists [97]. To optimally leverage free-text reports to train
network, we can automatically turn these reports into precise
labels or structured annotations [97]. However, most PACS
databases are unavailable.
D. DRUG DISCOVERY
Drug discovery is the process of finding drug candidates
that can be used as new drugs [103]. The motivation for
drug discovery is because there are no suitable medical prod-
ucts for certain diseases [104]. Drug discovery is generally
divided into the following steps: target identification and
validation, screening and lead discovery, lead optimization
and retrosynthetic analysis [103], [105]. Despite advances in
biotechnology, drug discovery remains an expensive, difficult
and inefficient process [106].
In target identification and validation phase, we need to
determine the pathogenic factors of the disease, from DNA
to RNA to protein characterization [107].
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TABLE 5: Data set for ALL diagnosis
Name Task Instances Types Modality Year
TARGET Phase I Determine molecular changes that
drive childhood cancers
200 subjects Clinical,
genetic
TXT 2009-
2018
BioGPS COG P9906 Evaluate a regimen in patients with
high risk B-precursor ALL
267 subjects Clinical,
genetic
TXT 2011
ALL-IDB Evaluate the algorithms for image
segmentation and classification
108 images Imaging JPG 2010
TABLE 6: Overview of datasets for breast cancer diagnosis.
MG stands for mammography.
Name Task Instance Types Modality
INbreast develop breast cancer
CAD systems
115 cases , 410
images
imaging MG
MIAS mammographic image
analysis research
322 images imaging MG
DDSM mammographic image
analysis research
2620 cases, 43
volumes
imaging,
expert
ground-truth,
metadata
MG
BCDR-
FMR
lesion classification 1010 cases, 3703
images
imaging,
metadata
MG
BCW lesion classification 569 instances, 32
attributes
imaging,
metadata
MG
TCGA-
BRCA
connecting cancer phe-
notypes to genotypes
139 cases,
230167 images
imaging,
clinical and
genomic data
MR,
MG
Lead discovery and drug screening refer to the process of
assessing the biological activity, pharmacological effects, and
medicinal value of a substance that may be used as a drug
using an appropriate method [108]. Drug screening mainly
includes high-throughput screening (HTS) and virtual drug
screening [104]. HTS methods can be performed by robots
at the same time for millions of tests, so the cost is very
high. Because real drug screening requires the construction
of large-scale compound libraries, extraction or cultivation
of a large number of target enzymes or target cells necessary
for experiments, and the need for complex device support,
Drug screening requires a huge investment. The virtual drug
screening method simulates the process of drug screening on
a computer, predicts the possible activity of the compound,
and then performs targeted physical screening of compounds
that are likely to become drugs.
The final stage of drug discovery is lead optimization
and retrosynthetic analysis. The purpose is to maintain the
advantageous properties of the lead while improving the
defects of the lead structure. Retrosynthetic analysis is to
generate a synthetic route for a given target molecule [109].
Retrosynthetic analysis is to give a desired target molecule,
using molecular compounds that can be directly synthe-
sized, to give several possible synthetic routes of the target
molecule [110]. The difficulty is that if the molecular com-
pound to be synthesized is very complicated, the chemist
may have to consult a lot of relevant literature, and also
carry out repeated practice analysis in order to finally obtain
several possible synthetic routes [111]. However, chemists
may not be able to find a reasonable synthetic route because
of knowledge or time constraints, or only find a few routes.
Many types of data are needed for drug discovery. At the
stages of target identification and validation as well as lead
optimization and retrosynthetic analysis, gene expression
data and molecular-level data are needed, including com-
pound structure, properties, and related chemical reactions.
In drug screening, we need a drug sensitivity database and
a toxicity database [107]. Several databases related to drug
discovery are listed in Table 7.
TABLE 7: Overview of datasets for drug discovery
Name Task Instance Types
Reaxys discover chemical
structures, properties
and reactions
more than 28 million
responses, more than
18 million substances,
and more than 4 mil-
lion documents
relevant literature,
precise compound
properties and
reaction data
SIOC for chemical research - compound structure
and identification,
natural products
and pharmaceutical
chemistry, chemical
literature, chemical
reactions and
comprehensive
information
PubChem
BioAssay
deliver free and easy
access to all deposited
data, and to provide
intuitive data analysis
tools [112]
500,000 descriptions
of assay protocols,
covering 5000 protein
targets, 30,000
gene targets and
providing over 130
million bioactivity
outcomes [112]
chemical structure
and biological
properties of small
molecules and RNAi
reagents [112]
TCM construct the first
traditional Chinese
medicine database for
molecular docking
simulation [113]
20,000 pure
compounds isolated
from 453 TCM
components [113]
molecular attributes,
substructures, TCM
components, and
TCM classifications
ChEMBL address a wide range
of drug discovery
problems
2,275,906 compound
records, 12,091 targets
compound structure,
biological or
physicochemical
measurements of
these compounds and
information on the
goals of these assays
arerecorded in a
structured form [114]
1) Gene expression database and molecular-level database
The Reaxys database is produced by Elsevier, and is a rich
database of chemical values and facts. Reaxys integrates
the contents of Beilstein, Patent and Gmelin into an unified
resource that includes more than 28 million responses, more
than 18 million substances, and more than 4 million docu-
ments. It helps users identify promising new projects, ter-
minate ineffective lead compounds, and design economical
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and high-yield synthetic routes that maximize time and cost
savings.
The Shanghai Institute of Organic Chemistry’s (SIOC)
database (http://www.organchem.csdb.cn) group is a compre-
hensive information system for chemical research and devel-
opment. It provides compound structure and identification,
natural products and pharmaceutical chemistry, chemical lit-
erature, chemical reactions and comprehensive information.
Chemical reaction condition retrieval is to search for match-
ing chemical reactions in the database by chemical reaction
conditions such as reactants, products, catalysts, solvents,
reagents, and the like. The user can search for the relevant
reaction by the reactant, the English name of the product, the
reaction conditions, the catalyst, etc.
The Taiwan traditional Chinese medicine (TCM)
database [113] is currently the largest non-commercial TCM
database in the world. This web-based database contains
more than 20,000 pure compounds isolated from 453 TCM
components [113]. All data are easily accessible to all
researchers. In the past eight years, many volunteers have
spent time in analyzing Chinese medicine ingredients in the
Chinese medical literature and building structural files for
each of the isolated compounds.
2) Lead discovery and drug screening database
PubChem BioAssay database [112] is a public resource
for archiving the chemical structure and biological prop-
erties of small molecules and RNAi reagents. The Pub-
Chem BioAssay database currently includes bioactivity from
high-throughput screening and medicinal chemistry stud-
ies [112]. In addition, the PubChem BioAssay database con-
tains dozens of high-throughput RNAi screens for complete
genomes. These data, combined with other NCBI resources,
make PubChem a public information system widely used in
chemical biology and drug discovery research [112].
ChEMBL [114] is an open, large-scale bioactivity database
containing information manually extracted from the medici-
nal chemistry literature (https://www.ebi.ac.uk/chembl). The
ChEMBL database currently contains information extracted
from more than 51,000 publications, as well as bioactive data
sets from 18 other databases [114]. The data mainly includes
screening results and bioactivity data.
V. DO STATE-OF-THE-ART AND
STATE-OF-THE-PRACTISE ALGORITHMS PERFORM A
GOOD JOB?
A. QUANTIFIED SELF
With wearable devices deployed in recent years, more and
more physiological and functional data is captured continu-
ously for healthcare applications [52]. In the previous work,
traditional statistical methods are widely used. There are two
challenges and opportunities for handling QS data. On one
hand, although deep learning has been applied in high per-
formance platforms successfully, it does not perform well on
low-power wearable devices due to resource limits [115]. On
the other hand, sensor data of QS is mostly time-series [52].
In the previous work, the data are usually analysed by
traditional technologies like linear regression or other sta-
tistical methods. For example, Angeles et al. [116] use sta-
tistical algorithms to distinguish between non-mimicked and
mimicked tests for all the Parkinson’s primary symptoms,
with very convincing differences. To evaluate the patients in
rehabilitation recovery progress [117], Chen et al. [118] use
some validation techniques, such as 10-fold cross-validation.
This technique can classify the types of exercise and deter-
mine if their postures are appropriate. The overall accuracy of
posture recognition is 88.26% and that of type classification
is 97.29% [118]. It is believed to be beneficial for patients to
effectively rehabilitate.
We summarize state-of-the-practise and state-of-the-art
work of applying machine learning for QS in Table 8. To
identify common daily living activities for chronic disease
management, Atallah et al. [119] use a two-stage Bayesian
classifier to evaluate the condition of patients with chronic
obstructive pulmonary disease (COPD). The development of
Bayesian classification framework can explain the errors in
sensor data, and classification accuracy of different activ-
ities [119]. Methods like SVM (support vector machines)
and decision trees are trained to classify the data [120]–
[122]. For human physical activity recognition, Ignatov et
al. [121] propose a method using k-nearest neighbor and
DNN as an alternative to process time-series data. Their
method has high accuracy. When using a set of segmentation
and KNN, it achieves nearly 96% recognition accuracy [121].
To recognize activity, Catal et al. [123] propose a method
that combines multiple classification methods such as J48
decision tree, Multi-Layer Perceptrons (MLP) and Logistic
Regression techniques. Using deep learning methods, includ-
ing CNN (convolutional neural networks), RBM (Restricted
Boltzmann machines), and DBN (deep belief networks),
from the input data, the machine can directly learn a set
of features which are discriminative [115], [124], [125]. Al-
sheikh et al. [126] use a method based on DBNs and RBMs.
The method uses multiple hidden layers to recognize activity.
This work proves that these models have better recognition
accuracy of human activities, using a large number of unla-
beled acceleration samples to extract unsupervised features
and avoid expensive manual features design in existing sys-
tems [126].
Nowadays, the information of the data requires efficient
ways of classification and analysis if deep learning is a good
choice in some cases [117]. Deep learning is a promising
technique that could extract information and infer from big
data by using multiple processing layers [127].
B. DISEASE CLASSIFICATION
Disease classification, which groups diseases together based
on their similarities, is expected to promote understanding
and curing human diseases [62]. The conventional methods
classify human diseases through 4 dimensions containing
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TABLE 8: The summary of algorithms used in QS.
Reference Method Modality Application Database Year
[120] GMM, HC,
K-means,
K-medoids, SC
time series data HAR none 2017
[116] statistical time series data Quantify
Parkinsonian
symptoms
none 2016
[121] LR, NN, SVM,
J48, KNN
time series data HAR none 2016
[122] adaboost time series data HAR WISDM 2016
[126] DBN and RBM time series data HAR WISDM,
Daphnet,
Skoda
2016
[118] cross-
validation
time series data Rehabilitation
Exercise
Assessment
for Knee
Osteoarthritis
none 2016
[123] ensemble of
classifiers
time series data HAR WISDM 2015
[125] DCNN time series data HAR Opp, Hand
Gesture
2015
[115] CNN time series data HAR none 2015
[124] CNN time series data HAR Opp,
Skoda,
Actitracker
2014
[119] Bayesian clas-
sifier
time series data chronic
obstructive
pulmonary
disease
none 2009
Abbreviation: GMM = Gaussian Mixture Model with Expectation-
Maximization; HC = a hierarchical method; SC = spectral cluster-
ing.
pathogen, the original component causing diseases, pathol-
ogy and clinical patient behavior. However, with the im-
provement of human gene analysis and molecular biology,
researchers obtain a large amount of relative information.
And with the molecular level information, our knowledge
network of diseases has been refreshed and our cognition
of diseases has also been improved. Consequently, these
two significant changes provide an appropriate opportunity
for researchers to develop more precise methods to classify
human diseases from the molecular level.
Table 9 shows a variety of mature algorithms relating to
classification and clustering. Though, at present many algo-
rithms of disease taxonomy has been developed, researchers
need to develop more effective and robust algorithms to
meet the needs of disease classification with the increase of
different type data of molecular biology.
Hoadley et al. [133] reclassified 12 kinds of cancer from
molecular level, which originate from different organs. In
the research, the cluster-of-cluster assignments (COCA) al-
gorithm, which is a kind of agglomerative hierarchical clus-
tering method using Pearson correlation as the distance mea-
surement, is adopted to cluster the genomic and proteomic
data from different platforms. According to the research
result, the 12 cancers conventionally classified according
to their original organs are uniformly reclassified into 11
major subtypes with their causes of gene and protein, which
provides a new idea to the cancer clinical treatment strategy.
Hoadley at al. [135] conduct a molecular reclassification of
33 cancer types from the TCGA platform. During the process
of the reclassification, researchers utilize iCluster algorithm,
a joint latent variable model-based clustering algorithm to
deal with different type data, to cluster molecular data in-
volving chromosome, DNA, mRNA, miRNA and protein
from TCGA. Based on the consequence of the study, re-
searchers re-cluster 33 cancer types into 28 cancer subtypes.
Besides, they discover and verify the dominated position of
cell-of-origin pattern in cancer molecular classification. The
molecular similarities of cancer subtypes contribute to the
improvement of future therapy of cancer [135].
Bailey at al. [131] identify various subtypes of pancreatic
ductal adenocarcinomas through genetic analysis. The non-
negative matrix factorization clustering, which uses the ma-
trix factorization technology to cluster samples, is exploited
to cluster recurring altering genes of 456 pancreatic cancer
patients. This study discovers 4 subtypes of pancreatic cancer
with respectively specific pathological characteristics, which
provides beneficial information for the inference of the de-
velopment of pancreatic cancer and a new idea of clinically
therapeutic strategy of pancreatic cancer [131].
Guinney et al. [132] construct a consensus classification
of colorectal cancer (CRC), since the translational and clin-
ical utility of gene expression-based subtyping is hampered
by discrepant results from different researches. Firstly, the
Markov cluster (MCL) algorithm is applied to obtain the
consensus molecular subtypes (CMS) from 6 CRC classifi-
cation systems. And then a random forest model is utilized to
classify new samples into CMS. The research classifies CRC
into 4 consensus molecular subtypes microsatellite instability
immune, canonical, metabolic and mesenchymal [132]. Each
subtype has the clear biological interpretability, which is very
important in the treatment of patients.
C. DISEASE DIAGNOSIS
1) Alzheimer’s disease (AD) diagnosis
Depending on severity, patients are usually diagnosed as
normal controls (NC), MCI or AD. Different materials such
as neuroimaging, biospecimen and genetic data are used to
diagnose AD. In the previous work, deep learning techniques
are extensively used to analyze medical imaging by many
researchers and have achieved good performance. Although
some studies [136], [137] show that biospecimens and
genetic data provide alternatives to neuroimaging in AD
diagnosis, those data is scarcely used to diagnose AD in
practice. So researchers should pay more attention to develop
comprehensive and integrative diagnosis method based on
different materials, which is likely to achieve much higher
precision.
Analyzing neuroimagings such as MRI and PET images
is a prevalent method for AD diagnosis. Jie et al. [138]
propose a manifold regularized multitask feature learning
method and then classify patients to three categories: AD,
MCI and NC. The algorithm reaches 95.03% accuracy tested
on MRI and PET images from ADNI, which contains 202
subjects: 51 AD patients, 99 MCI patients, and 52 NC.
11
Zhang et al.: Landscape of Big Medical Data: A Pragmatic Survey on Prioritized Tasks
TABLE 9: Summary of algorithms for disease classification
Reference Method Modality Application Data Year
[128] iCluster [129] genomic Clustering cancer from chromosome,DNA, mRNA and protein level. TCGA 2018
[130]
random forest, DIANA clustering,
two-dimensional hierarchical
clustering
genomic Classifying colorectal cancer with geneinformation of cancer cells. GEO 2017
[131] non-negative matrix factorization genomic Clustering pancreatic cancer information ofrecurring altering genes. APGI 2016
[132] Markov cluster (MCL) algorithm genomic
Reclassifying 6 classification system of
Colorectal cancer into 4 consensus
molecular subtypes.
CCLE,
GSK,
Sanger
2015
[133] cluster-of -clusterassignments(COCA) algorithm genomic
Clustering 12 cancer types from gene and
protein level to find new subtypes of
the cancer.
TCGA 2014
[134] iCluster [129] genomic Cancer subtype classification and discovery. TCGA 2012
Suk et al. [139] utilize sparse regression models as target-
level representation learner and build a deep convolutional
neural network for AD identification. The algorithm reaches
90.28% accuracy on a baseline MRI dataset of 805 subjects,
including 186 AD, 393 MCI, and 226 NC, from the ADNI
database. Shi et al. [140] use thin-plate spline (TPS) based
nonlinear feature transformation and stack denoising sparse
auto-encoder (DSAE) deep fusion for AD staging analysis,
and the approach reaches 91.95% accuracy. The experiment
is performed on a sub dataset of MRIs together with their
whole brain masks selected from ADNI, which contains
338 subjects: 94 patients with AD, 121 with MCI and 123
NCs. Shi et al. [141] develop a multi-modal stacked deep
polynomial networks (MM-SDPN) algorithm to fuse and
learn feature representation from multi-modal neuroimaging
data for AD diagnosis, and the approaches reach 97.13%
accuracy. Data from ANDI are used here, consisting of MRI
and PET images from 202 subjects: 51 AD patients, 99 MCI
patients, and 52 NC. The performances of different classifiers
are summarized in Table 10.
Several studies indicate that CSF biomarkers provide alter-
natives to MRI and PET images in AD diagnosis. Hansson et
al. [136] indicate that tau/Aβ ratios are as accurate as semi-
quantitative PET image assessment. Mattsson et al. [142]
provide evidence that when identifying early AD, CSF tau
and 18F-AV-1451 PET have similar performance but MRI
measures have lower area under the receiver operating char-
acteristic curve (AUROC). Besides, they find when identify-
ing mild to moderate AD, 18F-AV-1451 PET is superior to
CSF tau.
Although genetic information is provided in ADNI, the
studies are limited mainly because of the nontrivial valida-
tion of correlations between genetic variants and phenotype.
However several studies show that certain genes are related to
AD. For instance, Lorenzi et al. [137] identify a link between
tribbles pseudokinase 3 (TRIB3) and the stereotypical pattern
of gray matter loss in AD.
TABLE 10: Classification result of different algorithms for
AD diagnosis
Reference AD vs. NC MCI vs. NC
ACC SEN SPE ACC SEN SPE
[141] 97.13 95.93 98.53 87.24 97.91 67.04
[140] 91.95 89.49 93.82 83.72 84.74 82.72
[139] 90.28 92.65 89.05 74.20 78.74 66.30
[138] 95.03 94.90 95.00 79.27 85.86 66.54
Abbreviation: AD = Alzheimer disease; MCI = mild cognitive
impairment; NC = normal controls; ACC = Accuracy; SEN =
Sensitivity; SPE = specificity.
2) Acute lymphoblastic leukemia (ALL) diagnosis
Microscopic examination of blood or bone marrow smears is
the only effective way to leukemia diagnosis [89]. Several
methods [89], [143]–[145] have been provided to classify
cells to be cancerous or noncancerous, and the most achieve
the accuracy more than 95%. For instance, Abdeldaim et
al. [145] present a computer-aided ALL diagnosis system,
which first segments each cell in the microscopic images,
and then classifies each segmented cell to be normal or
affected. The experiment based on ALL-IDB2 achieves the
accuracy of 96.42% with a KNN classifier. Gene data may
also be used to diagnose ALL. For instance, by examining
gene expression profiles, Willman et al. [96] find that the
clusters are associated with either specific clinical features or
treatment response characteristics in the children with high
risk B-precursor ALL.
3) Breast Cancer Diagnosis
Machine learning approaches have been extensively used in
the diagnosis of breast cancer. Researchers have focused on
devising better algorithms to automate the detection of can-
cerous cells. Table 13 shows the state-of-the-art algorithms
diagnosing breast cancer.
Huynh et al. [161] learn the features on mammography
pictures by the use of CNN algorithm, and an SVM model is
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TABLE 11: Overview of papers for AD diagnosis
Reference Method Modality Application Data Year
[141] MM-SDPN MRI, PET AD diagnosis ADNI 2018
[136] Comparation CSF, PET Clinical progression pre-
diction
ADNI,
BioFINDER
2018
[142] Comparation CSF, PET AD diagnosis BioFINDER 2018
[137] Statistic Genetic, PET Genetic underpinnings of
AD
ADNI 2018
[140] DSAE MRI AD diagnosis ADNI 2017
[139] CNN MRI AD diagnosis ADNI 2016
[138] Laplacian
regularizer
MRI, PET, CSF AD diagnosis ADNI 2015
Abbreviation: CNN = convolutional neural network; DSAE = stacked denoising sparse auto-encoder; MM-SDPN = multimodal stacked deep
polynomial networks.
TABLE 12: Overview of papers for ALL diagnosis
Reference Method Modality Application Data Year
[145] K-NN JPG Image segmentation ALL-IDB 2018
[89] Fuzzy C Means JPG Image segmentation Taken form
Google
2017
[144] K-Means JPG ALL classification Isfahan Al-Zahra
and Omid hospi-
tal
2015
[143] Ensemble classi-
fier
JPG ALL classification Ispat General
Hospital
2014
[96] Cluster TXT ALL feature selection TARGET 2013
used to classify the derivative features into three categories,
which include benign, cystic and malignant. They apply their
algorithm on a dataset which include 607 breast images and
procure an AUC (Area Under the Curve) of 86% [161].
Wang et al. [151] develop a 12-layer CNN for breast
arterial calcification (BAC) detection. The micro-calcium
detection and diagnosis algorithm yields 96.24% accuracy,
and the inferred micro-calcium lesion is close to the ground
truth [151].
Sun et al. [149] present a semi-supervised learning method
based on graph by the use of CNN to diagnose breast cancer.
They obtain an AUC of 88.18% on a dataset which contains
both labeled and unlabeled data [149].
Kooi et al. [148] develop a computer-aided diagnosis
technique to diagnose benign solitary lesions from malignant
masses on digital mammogram. The algorithm obtains an
AUC of 87%, which is better than the other algorithms [148].
Zhu et al. [147] propose deep end-to-end networks for
lesion classification on digital mammography pictures. They
also explore three different modes to develop deep CNN net-
works for whole mammogram diagnosis [147]. They apply
their algorithm on the INbreast dataset, and the experimental
results show the robustness of their networks [147].
So far, mammography has been analyzed by much pre-
vious work with deep learning algorithms [10]. But there
are little previous work that analyzes breast MRI, US, or
digital breast tomosynthesis. In the near future, these other
modalities will probably receive much attention [10].
Because of most of the large digital datasets can not be
used for free, many research efforts apply their algorithm
on stale and small databases, which results in precarious
AUC [149]. Much previous work has tackled this issue by
employing semi-supervised learning [149], weakly super-
vised learning [160], and transfer learning [148].
D. DRUG DISCOVERY
Target identification and validation For a disease, de-
termining its target is a challenging and time-consuming
task. Lamb et al. [169] create the first set of reference sets
of gene expression profiles derived from cultured human
cells treated with biologically active small molecules, and
pattern matching software to mine these data. Madhukar et
al. [170] develop a platform that integrates multiple data
types into a Bayesian machine learning framework to predict
the goals and mechanisms of small molecules. They use
publicly available BANDIT data set to achieve approximately
90% accuracy on more than 2,000 different small molecules-
significantly better than any other published target recogni-
tion platform.
Retrosynthetic analysis Retrosynthetic analysis has a
large search space, which is the biggest challenge of drug
discovery. Law et al. [171] design a retrosynthetic analy-
sis tool utilizing automated retrosynthetic rule generation.
However, the algorithm does not have good efficiency and
effectiveness. Inspired by alphgo, Segler et al. [110] use
Monte Carlo tree search (MCTS) and symbolic artificial
intelligence to discover retrosynthetic routes. The Waller
team [110] integrate concepts such as deep neural networks
and reinforcement learning into a common architecture, and
propose an algorithmic framework using three different neu-
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TABLE 13: Summary of breast cancer diagnosis.
Reference Techinique Modality Application DB Year
[146] GAN MG Mabss segmentation INbreast,
DDSM-BCRP
2018
[147] MIL-
CNN
MG Lesion classification INbreast 2017
[148] CNN MG Lesion classification INbreast,
DDSM
2017
[149] CNN MG Semi-supervised CNN for
classification of masses
FFDM 2017
[150] CNN MRI Breast and fibro glandular
tissue segmentation
Self-produced
data
2017
[151] CNN MG Detection of cardiovascu-
lar disease based on vessel
calcification
Self-produced
data
2017
[152] M-CNN H&E Mitosis detection AMIDA 2016
[153] SAE US, CT Lesion classification Self-produced
data
2016
[154] CAE MG Breast density segmenta-
tion, breast cancer risk
scoring
Self-produced
data
2016
[155] RBM US Lesion classification Self-produced
data
2016
[156] CNN TS Mass detection DDSM 2016
[157] CNN MG Lesion classification BCDR 2016
[158] CNN MG Tissue classification using
regular CNNs
Self-produced
data
2016
[159] CNN MG Lesion classification Inbreast 2016
[160] CNN MG Mass localization TCGA 2016
[161] CNN MG Mass classification Collected from
University
of Chicago
Medical Center
2016
[162] CNN MG Lesion classification Self-produced
data
2016
[163] CNN MG Cancer risk score Self-produced
data
2016
[164] CNN TS Micro calcification detec-
tion
Collected from
the University
of Michigan
2016
[165] CNN TS Transfer mammographic
masses to tomosynthesis
Self-produced
data
2016
[166] CNN MG Mass classification Inbreast 2016
[167] CNN MG Lesion classification MIAS 2015
[168] ADN MG,US Mass classification Self-produced
data
2012
Abbreviation: M-CNN= Multi-Stream CNN; MIL-CNN= Multi-
instance Learning CNN; CAE= Convolutional Auto-Encoders;
SAE= Stacked Auto-Encoders; H&E= Hematoxylin & Eosin His-
tology Images; MG= Mammography; US= Ultrasound; CT= Com-
puted Tomography.
ral networks together with MCTS(3N-MCTS). Deep neural
networks are used to predict which molecules will participate
in the reaction. Monte Carlo search tree is used to predict
the likelihood of a reaction. Compared with traditional rule-
based retrosynthesis analysis, this work borrows a lot of ideas
from deep neural network and reinforcement learning, which
is an important improvement to the traditional methods. The
3N-MCTS method is applied to the Reaxys database. Chem-
ical reactions recorded before 2015 are used as training data,
and chemical reactions recorded after 2015 are used as test
data. Compared with two traditional approaches: Heuristic
BFS and Neural BFS, 3N-MCTS solves 87.12% of the test
set’s problems while Neural BFS solves 45.6% and Heuristic
BFS solves 84.24% [171] [110].
TABLE 14: Summary of state-of-the-art work for drug dis-
covery
Reference Techinique Application DB Year
[170] Bayesian machine
learning framework
target identification
and validation
public data 2017
[171] automated retrosyn-
thetic rule genera-
tion
retrosynthetic analysis MOS 2009
[110] MCTS, DNN retrosynthetic analysis Reaxys
chemistry
database
2018
[108] Multitask Networks drug screening 259
datasets
2015
[172] DCNN bioactivity prediction ChEMBL,
DUDE
2015
Abbreviation: MOS = Accelrys and the Beilstein Crossfire reaction
database; MCTS = Monte Carlo tree search; DNN = deep neural
networks; DCNN = Deep Convolutional Neural Network;.
Drug screening In drug screening, virtual screening has
been a hot topic because of its high time overhead of high-
throughput screening and high cost of consumption. The
researchers at Google and Stanford [108] are working to
develop virtual screening techniques using deep learning to
replace or enhance traditional high-throughput screening pro-
cesses and increase the speed and success rate of screening.
By applying deep learning, researchers can share information
across numerous experiments across multiple targets. They
obtain data from 259 public datasets and divide the data into
four groups, using a 5-fold cross-validation in group PCBA to
achieve an AUC value of 0.873. The 5-fold cross-validation
AUC scores in the grouped MUV and Tox21 reach 0.841
and 0.818, respectively. In drug screening, it is important to
predict the ability of binding between molecules. Wallach
et al. [172] use structure-based deep-convolutional neural
network - AtomNet to predict bioactivity. They evaluate the
accuracy of the model on the famous Directory of Useful
Decoys Enhanced (DUDE) benchmark platform. AtomNet
reaches or exceeds 0.9 AUC on 59 targets. Two previous
research efforts [108] [172] use state-of-the-art deep learning
techniques to effectively reduce the cost of drug screening
and improve accuracy.
In one word, each step in drug discovery has relatively
mature algorithms and platforms [173]. We summarize the
related algorithms in Table 14.
VI. ARE THERE ANY BENCHMARKS FOR MEASURING
ALGORITHMS, SYSTEMS FOR BIG MEDICAL DATA?
Benchmark is the foundation of systems and algorithms
design, optimization, and evaluation. Many algorithms and
systems have been widely used in medical domains. To
explore processing efficiency and tackling potential bottle-
necks, domain-specific benchmarks are essential for the de-
velopments and optimizations of that domain. However, in
terms of big medical data domain, the diversity of disease
taxonomies, the complexity of clinician research tasks, and
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the heterogeneity of medical data pose great challenges in
constructing a comprehensive and fair benchmark.
An ideal medical benchmark should cover a broad spec-
trum of big medical data processing. To cover the data diver-
sity, a benchmark should include electronic health records,
laboratorial data, and QS data. To assure the algorithm di-
versity, a benchmark should consist of not only traditional
machine learning but also deep learning algorithms.
At present, there is no comprehensive big medical data
benchmark suite. The previous benchmarking efforts only
cover limited perspectives of big medical data. Table 15 com-
pares different medical benchmarks from the perspectives of
application domain, data type, data size, algorithm, system,
metric and publishing year.
Liu et al. [9] propose a benchmark database for fall de-
tection. This database [9] collects data from 50 males and
females ranging from 21 to 60 years of age, 1.55 to 1.90 m
in height, and 40 to 85 kg in weight. They use four baseline
algorithms (ANN, KNN, SVM, and kernel Fisher discrimi-
nant) to evaluate the reliability of the database compared to
the previous ones.
MURA [174] is a benchmark database of musculoskeletal
radiographs containing 40,561 multi-view radiographic im-
ages collected from 12,173 patients, with a total of 14,863
studies covering seven study types—elbow, finger, forearm,
hand, humerus, shoulder, and wrist. Each study is labelled as
normal or abnormal manually.
ChestX-ray8 [180] is a hospital-scale chest X-ray database
and benchmarks on weakly-supervised classification and lo-
calization of common Thorax diseases. It comprises 108,948
frontal-view X-ray images of 32,717 unique patients with the
text-mined eight disease image labels, from the associated
radiological reports using natural language processing [180].
AD DREAM Challenge [91] is a benchmark suite aiming
to evaluating the state-of-the-art algorithms in predicting AD,
based on high dimensional, publicly available genetic and
structural imaging data. The training data consist of individ-
uals participating in the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) [181].
Christov et al. [176] present a medical benchmark based on
a blood transfusion process. The benchmark [176] consists
of a blood transfusion process definition, a set of properties
or requirements, and a set of bindings between the blood
transfusion properties and process definition.
IICBU 2008 [177] is a benchmark suite for biological
image analysis. It [177] provides a biological image datasets
and a set of practical real-life imaging problems in biology,
including the examples of organelles, cells and tissues. They
can be used to evaluate different biological image analysis
methods.
BigDataBench [175], [182] provides a big data and AI
benchmark covering search engine, e-commerce, social net-
work, multimedia, and bioinformatics domains. As for bioin-
formatics, it provides two workloads—SAND and BLAST.
Among them, SAND [179] is a set of modules for genome
assembly. It performs distributed computing and supports
easily deployments on large-scale clusters, clouds or grids.
Totally, it consists of two steps including candidate filter-
ing and alignment. As for datasets, it provides genome se-
quence data with three data scales—small, medium and large.
BLAST [178] is a parallel basic local alignment searching
workload. It is used to compare nucleotide or protein se-
quences with the database and find the similarities.
VII. WHAT IS THE PERFORMANCE GAP OF
STATE-OF-PRACTISE AND STATE-OF-THE-ART
SYSTEMS FOR HANDLING BIG MEDICAL DATA
CURRENTLY OR IN FUTURE?
Many state-of-the-art and state-of-practise systems have
been widely used in big medical data. However, the charac-
teristics of medical data pose great challenges to both data
storage and processing.
Multiple medical data processing systems are proposed
to handle large-scale medical data. For medical imaging
data analysis, PAIS (Pathology Analytical Imaging Stan-
dards) [183] provides a data model to manage image data,
using a spatial DBMS based architecture. Hadoop-GIS [184]
adopts a MapReduce-based solution to support complex
queries for analytical pathology imaging. For genome data
analysis, GATK [185] is a MapReduce-based genome anal-
ysis toolkit for analyzing next-generation DNA sequencing
data. IMG [186] is an integrated microbial genomes database
and comparative analysis system. For medical text data,
Neamatullah et al. [187] provide a system to process text-
based patient medical records.
However, the sources and types of medical data are usu-
ally multifarious and integrated. For example, the electronic
health record (EHR) dataset, which is used in a recent re-
search effort [85], has thousands of feature dimensions and
contains patient demographics, provider orders, diagnoses,
procedures, medications, laboratory values, vital signs, and
flowsheet data [85], covering images, text, structured, or
un-structured data types and sources. These dimensions are
not processed and learned individually, and conversely, they
are combined to detect and diagnose diseases cooperatively.
Under this circumstance, the storage and processing systems
are required to integrate different data sources and types.
Existing systems targeting a specific data type like medical
images can not process other data types. To the best of our
knowledge, there exists no such a system that can support
multi-source and heterogeneous data storage and processing
in the big medical domain. Previous work [85] develops a
new data structure—FHIR standard to handle their hetero-
geneous data. However, considering the diversity of disease
taxonomies and the variety of medical data, developing a new
data structure or a new system for one or more data types
or data sources only provide a case-by-case solution. Hence,
there is an urgent need for a new comprehensive system that
satisfies the processing requirements of big medical data.
Nowadays, deep learning systems, e.g. TensorFlow [188],
Caffe [189], are used to handle medical data. However, since
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TABLE 15: Overview of medical data benchmarks.
Reference Application Domain Data Type Data size Algorithm System Metric Year
[9] Fall detection sensor data 9, 379 files the artificial neutral network, k
nearest neighbor, support vector
machine, and kernel Fisher dis-
criminant
none Accuracy, Speci-
ficity, Sensitivity
2018
[174] abnormality detection
in musculoskeletal ra-
diographs
image data 40,561 169-layer DenseNet baseline
model
none AUC, Specificity,
Sensitivity
2017
[175] Gene unstructed text data gene sequence: 20MB-7GB, gene
assembly: 100MB-13GB
offline analysis Work Queue,
MPI
system and archi-
tecture metrics
2016
[91] Alzheimer’s Disease
(AD) prediction
Clinical data;
Genotype data;
Magnetic resonance
image data
767 training samples for question
one; 176 CN samples for ques-
tion two; 628 training samples for
question three
AD prediction algorithms none Balanced
accuracy, AUC
2016
[176] blood transfusion pro-
cess
none none none none none 2010
[177] biological image anal-
ysis
Image (TIFF for-
mat)
9 datasets, 4,073 images WND-CHARM multi-purpose
image classification
none Accuracy 2008
[178] nucleotide or protein
sequences
Nucleotide, Peptide 209,775,348 loci,
263,957,884,539 bases, from
209,775,348 reported sequences
parallel basic local alignment
search
MPI execution time 2003
[179] genome assembly Text 4 datasets, 41,861,131 Reads candidate filtering and alignment Work Queue none -
these systems are general-purpose deep learning processing
framework without specific optimizations for big medical
data, they have inefficiencies considering complex clinician
research tasks. As illustrated above, EHR dataset [85] has
thousands of correlative feature dimensions covering images,
text, structured, or un-structured data types and sources, so
the researchers not only need to conduct time-consuming
data conversion so as to suit for the data input requirements
of the above systems, but also need to correlate those data
manually to collect all the data for each patient.
VIII. ARE WE READY FOR WORKING TOGETHER?
The tendency to utilize computing technologies in
medicine science is indispensable in the future for two rea-
sons: on one hand, a large amount of high quality data has
been accumulated in the medicine fields with the fast-paced
medical development. On the other hand, machine learning
techniques have performed a good job in routine tasks, and
the researchers of both fields have already made progress in
many aspects of medicine, i.e., automatic disease diagnosis.
However, we notice that the practical and wide application
of machine learning techniques to clinical therapy is limited
by several significant problems: first, the development of
data-driven AI in the directions of clinical medicine has been
restricted by the low degree of clinical practice digitization
and the difficulty of sharing data. Second, clinical practices
cover exceedingly complex scenarios while current machine
learning techniques merely have a good performance in the
scenarios where the conditions are described explicitly. Thus,
we believe that several prerequisites should be met with
for the sake of an effective and efficient multidisciplinary
cooperation. First, the digitized degree of clinical practice
and the sharing of clinical data should be improved be-
cause these two issues limit the computer experts to deepen
their understanding on clinical medicine. Second, the unified
criteria of the case utilizing AI or other machine learning
techniques in clinical tasks should be set up to help experts
of both fields to validate and share the knowledge among
each other. Benchmarks will play an unique role in setting up
those unified criteria of the case utilizing AI in clinical tasks.
Third, the multidisciplinary education among computing and
medicine sciences should be promoted to provide sufficient
talent with comprehensive abilities.
IX. CONCLUSION
In this paper, we—a group of life scientists, clinicians,
computing scientists and engineers perform a comprehen-
sive survey on big medical data, which is heterogeneous,
high-dimensional, embodying a large mixture of signals and
errors, and significantly different from other domain data.
We investigate the prioritized tasks in clinician practices and
research: quantified self (QS), disease classification, disease
diagnosis, and drug discovery. We found publicly availably
data sets that can be utilized for those tasks are not limited
to its scale, but also its single data source. The previous
work demonstrates the potential of incorporating machine
learning techniques into clinician practices. However, its high
accuracy is achieved on the static data. In reality, the clinician
practitioners work in an open environments, so we need set
up the realistic benchmarks that can mimic the way that the
clinician practitioners handle the data for different medical
data purposes. The sources and types of medical data are
usually multifarious and integrated. These dimensions are
not processed and learned individually, and conversely, they
are combined to detect and diagnose diseases cooperatively.
To the best of our knowledge, there exists no such a sys-
tem which can support multi-source and heterogeneous data
storage and processing in the big medical domain. Also,
we discuss several prerequisites for the sake of an effective
and efficient cooperation among life scientists, clinicians,
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computing scientists and engineers.
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